Drug Trial Radar · NCT07872033
Aleniglipron Hepatic Impairment Study
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Oct 29, 2026
Primary completion
Aug 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the PK of aleniglipron in participants with Hepatic Impairment to establish scientifically guided dosing recommendations in these special patient populations.
Conditions
- Hepatic Impairment
Interventions
AleniglipronDrug
administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK parameters including but not limited to AUC0-tTime frame: Baseline to Day 5 (Part 1)
- PK parameters including but not limited to AUC0-infTime frame: Baseline to Day 5 (Part 1)
- PK parameters including but not limited to CmaxTime frame: Baseline to Day 5 (Part 1)
- PK parameters including but not limited to AUC0-tTime frame: Baseline to Day 5 (Part 2)
- PK parameters including but not limited to AUC0-infTime frame: Baseline to Day 5 (Part 2)
- PK parameters including but not limited to CmaxTime frame: Baseline to Day 5 (Part 2)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Orlando, Florida · Recruiting
Research Site
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.